B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis

Biomark Med. 2014;8(3):395-403. doi: 10.2217/bmm.13.124.

Abstract

Aim: To investigate serum levels of B-cell activating factor (BAFF) in the patients with polymyositis (PM) and dermatomyositis (DM), and to systematically examine the association between serum BAFF levels and disease activity in PM/DM patients.

Patients & methods: A cross-sectional analysis included 92 PM/DM patients and 25 healthy control subjects. A longitudinal study followed 24 patients. Serum BAFF concentrations were detected by the ELISA method.

Results: Serum BAFF levels in PM/DM patients were significantly higher than those in healthy controls. A cross-sectional assessment revealed a modest correlation between serum BAFF levels and global disease activity and a mild correlation between serum BAFF levels and muscle disease activity. The longitudinal study showed that serum BAFF levels modestly correlated with global disease activity and muscle disease activity.

Conclusion: Resulting data showed high serum BAFF levels in PM/DM patients and suggested BAFF as a serological biomarker for PM/DM disease activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • B-Cell Activating Factor / blood*
  • Biomarkers / blood*
  • Cross-Sectional Studies
  • Dermatomyositis / diagnosis*
  • Dermatomyositis / metabolism
  • Enzyme-Linked Immunosorbent Assay*
  • Humans
  • Longitudinal Studies
  • Middle Aged
  • Polymyositis / diagnosis*
  • Polymyositis / metabolism

Substances

  • B-Cell Activating Factor
  • Biomarkers